

# The Essential Role of PP1 $\beta$ in *Drosophila* Is to Regulate Nonmuscle Myosin<sup>□</sup>

Natalia Vereshchagina,\* Daimark Bennett,\* Balázs Szöör, Jasmin Kirchner, Sascha Gross, Emese Vissi, Helen White-Cooper, and Luke Alphey<sup>†</sup>

Department of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom

Submitted February 19, 2004; Revised July 2, 2004; Accepted July 12, 2004

Monitoring Editor: Lawrence Goldstein

**Reversible phosphorylation of myosin regulatory light chain (MRLC) is a key regulatory mechanism controlling myosin activity and thus regulating the actin/myosin cytoskeleton. We show that *Drosophila* PP1 $\beta$ , a specific isoform of serine/threonine protein phosphatase 1 (PP1), regulates nonmuscle myosin and that this is the essential role of PP1 $\beta$ . Loss of PP1 $\beta$  leads to increased levels of phosphorylated nonmuscle MRLC (Sqh) and actin disorganization; these phenotypes can be suppressed by reducing the amount of active myosin. *Drosophila* has two nonmuscle myosin targeting subunits, one of which (MYPT-75D) resembles MYPT3, binds specifically to PP1 $\beta$ , and activates PP1 $\beta$ 's Sqh phosphatase activity. Expression of a mutant form of MYPT-75D that is unable to bind PP1 results in elevation of Sqh phosphorylation in vivo and leads to phenotypes that can also be suppressed by reducing the amount of active myosin. The similarity between fly and human PP1 $\beta$  and MYPT genes suggests this role may be conserved.**

## INTRODUCTION

Nonmuscle myosin II, a molecular motor closely related to vertebrate smooth muscle myosin, powers the actomyosin cytoskeleton. It is required for the coordinated changes in the shape and position of individual cells during morphogenesis as well as for cytokinesis and other cell movements. Nonmuscle myosin II activity is also modulated by metastasis-related and tumor suppressor genes (reviewed Bresnick, 1999; Matsumura *et al.*, 2001; Sellers, 2000; Somlyo and Somlyo, 2000).

The regulation of nonmuscle myosin is thought to be broadly similar to that of vertebrate smooth muscle myosin (Bresnick, 1999; Sellers, 2000). Contraction and relaxation of vertebrate smooth muscle are regulated by the reversible phosphorylation of myosin regulatory light chain (MRLC), principally on Ser-19. The motor activity of smooth muscle myosin is regulated by the balance of activatory phosphorylation, leading to muscle contraction, and inhibitory dephosphorylation, leading to relaxation. The spectrum of stimulating kinases includes myosin light-chain kinase (MLCK), Rho-associated protein kinase (ROK), p21-associated kinase (PAK), integrin-linked kinase (ILK) and leucine zipper-interacting protein kinase (Dlk/ZIP kinase; Somlyo and Somlyo, 2000; MacDonald *et al.*, 2001; Winter *et al.*, 2001; Kiss *et al.*, 2002). The antagonistic protein phosphatase is the catalytic subunit of type 1 serine/threonine protein phosphatase (PP1c) in association with its myosin phosphatase targeting subunit MYPT1 or MYPT2, and a small subunit of

unknown function (reviewed by Hartshorne, 1998). These kinases and phosphatases are themselves subject to regulation by reversible phosphorylation, for example ROK not only phosphorylates and activates MRLC, but also phosphorylates MYPT1 and inhibits MRLC dephosphorylation (reviewed Kaibuchi *et al.*, 1999; Somlyo and Somlyo, 2000). The nonmuscle roles of these myosin-regulating kinases are less clear, though at least one (ROK) also regulates nonmuscle myosin II in both mammals and *Drosophila*. Similarly, though PP1 is often assumed to be the major nonmuscle MRLC phosphatase, PP2A has also been implicated (Holst *et al.*, 2002). The various phosphorylation events have been investigated biochemically, but little is known about their physiological significance, particularly in nonmuscle cells.

*Drosophila* nonmuscle myosin II heavy chain zipper (*zip*) and regulatory light chain spaghetti squash (*sqh*) are essential for the normal development of a very wide range of cells and tissues (Karess *et al.*, 1991; Young *et al.*, 1993; Edwards and Kiehart, 1996; Hudson and Cooley, 2002). *Drosophila* Rho-kinase (Drok) phosphorylates both Sqh and DMBS (the single *Drosophila* homolog of MYPT1/2; Mizuno *et al.*, 2002; Tan *et al.*, 2003). By analogy to the vertebrate smooth muscle system it was proposed that this phosphorylation activates myosin and inhibits myosin phosphatase.

PP1 is involved in the regulation of many cellular functions including glycogen metabolism, muscle contraction, and mitosis (reviewed Bollen, 2001; Cohen, 2002). In *Drosophila*, the four genes encoding isoforms of PP1c are named by their chromosome location and subtype: PP1 $\beta$ 9C, PP1 $\alpha$ 13C, PP1 $\alpha$ 87B, and PP1 $\alpha$ 96A (Dombrádi *et al.*, 1990b, 1993). Of these, PP1 $\alpha$ 87B contributes 80% of the total PP1 activity, therefore the phenotypes of PP1 $\alpha$ 87B loss of function mutants (Axton *et al.*, 1990; Dombrádi *et al.*, 1990a; Baksa *et al.*, 1993) may be due to a loss of overall PP1 activity, rather than identifying specific functions unique to the PP1 $\alpha$ 87B protein. Mice and humans have three PP1 genes: PP1 $\alpha$  and PP1 $\gamma$  are related to the fly PP1 $\alpha$  genes, although

Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.E04-02-0139. Article and publication date are available at [www.molbiolcell.org/cgi/doi/10.1091/mbc.E04-02-0139](http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E04-02-0139).

<sup>□</sup> The online version of this article contains supplemental material accessible through <http://www.molbiolcell.org>.

\* These authors contributed equally to this work.

<sup>†</sup> Corresponding author. E-mail address: Luke.Alphey@zoo.ox.ac.uk.

PP1 $\delta$  (also known as PP1 $\beta$ ) corresponds to fly PP1 $\beta$ . Of the mammalian genes, functional analysis by gene knockout in mice has so far only been performed for PP1 $\gamma$  (Varmuza *et al.*, 1999). This knockout eliminated both the widely expressed PP1 $\gamma$  1 and the testis-specific PP1 $\gamma$  2. Homozygous mutant female mice were viable and fertile; homozygous mutant males were viable but sterile, with defects in spermatogenesis. Presumably the somatic and female germline functions of PP1 $\gamma$  are redundant with PP1 $\alpha$  and/or PP1 $\delta$ .

The *in vitro* biochemical activities of the PP1c isoforms are very similar. However, genetic analysis provides a powerful approach to analyze the specific, nonredundant functions of each isoform. We previously showed that the *Drosophila* PP1 $\beta$  catalytic subunit gene PP1 $\beta$ 9C corresponds to *flapwing* (*flw*), weak alleles of which are viable but flightless (Raghavan *et al.*, 2000). The semilethality of a strong allele, *flw*<sup>6</sup>, demonstrated that PP1 $\beta$  is essential in flies. *flw*<sup>6</sup> larval body wall muscles appeared to form normally, but then detached and degenerated, leading to a semiparalyzed larva that could not feed properly (Raghavan *et al.*, 2000). In addition to muscle defects, the occasional male *flw*<sup>6</sup> survivors were sterile and had blistered wings, indicating a nonredundant role for PP1 $\beta$ 9C in nonmuscle cells as well as in muscles.

Here we show that the essential role of PP1 $\beta$  in flies is to regulate nonmuscle actomyosin. The lethality of strong *flw* (PP1 $\beta$ ) mutants was suppressed by reducing the level of phospho-Sqh (MRLC), either using nonphosphorylatable point mutants of *sqh* or by reducing the gene dosage of key regulators such as *Rho1* or *RhoGEF2*. *flw* mutants were also suppressed by reducing the gene dosage of nonmuscle myosin heavy chain (*zipper*). Clones of ovarian follicle cells mutant for *flw*<sup>6</sup> had increased levels of phospho-Sqh, leading to disorganized or absent F-actin and to increased levels of myosin. Therefore, although PP1 isoforms collectively have many known roles, the essential, nonredundant role for PP1 $\beta$  in *Drosophila* is in the regulation of nonmuscle myosin activity and actin organization.

*Drosophila* has been reported to have only one MYPT homolog, named DMBS (Mizuno *et al.*, 2002; also known as DMYP, Tan *et al.*, 2003). We demonstrate that DMBS binds both  $\alpha$  and  $\beta$  isoforms of PP1 and is therefore unlikely to mediate a PP1 $\beta$ -specific function. However we have also identified a *Drosophila* PP1 $\beta$ -specific regulatory subunit, MYPT-75D, which is similar to mammalian MYPT3, a prenylated MYPT1/2 paralog (Skinner and Saltiel, 2001). MYPT-75D binds specifically to PP1 $\beta$  *in vitro* and the two proteins coimmunoprecipitate from fly extracts. We show that MYPT-75D can stimulate PP1 $\beta$ 's Sqh phosphatase activity *in vitro* and that MYPT-75D, PP1 $\beta$  and Sqh proteins coimmunoprecipitate. Expression of a nonPP1 binding form of MYPT-75D in flies results in elevation of phospho-Sqh and phenotypic consequences that can be suppressed by reducing the level of Sqh phosphorylation. We conclude that PP1 $\beta$  is targeted to Sqh by MYPT-75D, where it performs an essential role in the regulation of Sqh phosphorylation, and hence myosin activity, for which other PP1c isoforms cannot substitute. The conservation of all of these components, including the PP1 $\alpha$  and  $\beta$  isoforms, suggests that regulation of nonmuscle myosin in mammals may also involve the activity of PP1 $\beta$  and an isoform-specific myosin targeting subunit.

## MATERIALS AND METHODS

### Fly Stocks

*w<sup>67c23</sup>, P[lacW](1)GO172 (flw<sup>7</sup>)* was kindly provided by Ulrich Schaefer and *Tm2<sup>18</sup>* by Andrew Dingwall. *PP1 $\alpha$ 87B* mutants were provided by Myles

Axton. *UAS MYPT-75D<sup>WT</sup>* and *UAS MYPT-75D<sup>F117A</sup>* were generated by *P* element-mediated germline transformation of a *y w* strain. Other *Drosophila* stocks were obtained from the Bloomington Stock Center.

### Screens for Dominant Suppressors of *flw*<sup>6</sup>

For ethyl methanesulfonate (EMS) mutagenesis, *w<sup>1118</sup>* males isogenic for all three autosomes were starved for 9–11 h and then fed a 1% sucrose solution containing 25 mM EMS for 20–24 h. Mutagenized males were crossed to *y cho sn flw<sup>6</sup>/FM6; cn bw; e; ci ey<sup>R</sup>* virgin females. Surviving *flw<sup>6</sup>* males from the F<sub>1</sub> progeny (*y cho sn flw<sup>6</sup>/Y; cn bw/+<sup>+</sup>; e/+<sup>+</sup>; ci ey<sup>R</sup>/+<sup>+</sup>*, where an asterisk indicates a mutagenized chromosome), were individually backcrossed to females of the parental *flw<sup>6</sup>* strain as were their FM6 brothers (*FM6/Y; cn bw/+<sup>+</sup>; e/+<sup>+</sup>; ci ey<sup>R</sup>/+<sup>+</sup>*), once it became apparent that surviving *flw<sup>6</sup>* F<sub>1</sub> males were invariably sterile. FM6 brothers of surviving F<sub>2</sub> *flw<sup>6</sup>* males were used to generate a line for further analysis. Segregation of the suppressor activity relative to autosomal markers allowed us to determine the chromosomal linkage of the new mutations.

Our initial screens used *y cho sn flw<sup>6</sup>* (Raghavan *et al.*, 2000). However, when we realized that *flw<sup>6</sup>* interacted with actomyosin genes, we removed *singed* (*sn*), which encodes an actin-bundling protein (Cant *et al.*, 1994). Removing *sn* made no obvious difference to the *flw* phenotype, but in all later experiments we used *w<sup>1118</sup> flw<sup>6</sup>* or *w<sup>67c23</sup> flw<sup>7</sup>*.

### Mapping Analysis

Modifiers were recombination mapped by mating *Su(flw)*/Balancer males to females carrying a multiply marked second (*al dp b pr cn c px sp/CyO*) or third (*ru h th st cu sr e ca/TM3, Sb*) chromosome. In the case of a suppressor on the second chromosome, F<sub>1</sub> *Su(flw)/al dp b pr cn c px sp* females were crossed to *al dp b pr Bl cn c px sp/CyO* males; equivalent crosses were used for the third chromosome, using *ru h th st cu sr Pr e ca/TM6B*. F<sub>2</sub> recombinant males were individually crossed to *y cho sn flw<sup>6</sup>/FM7c* females to score suppression of *flw<sup>6</sup>*.

### Isolation of MYPT-75D

The two-hybrid screen of 5 × 10<sup>6</sup> *Drosophila* 3rd instar larval cDNAs, using PP1 $\beta$ 9C as bait, was described in Bennett and Alphey (2002) and Bennett *et al.* (1999). Database searches and sequencing revealed that BDGP clone LD46604 (Berkeley *Drosophila* Genome Project/HHMI EST Project, unpublished results) contained the entire MYPT-75D coding region.

### MYPT-75D Expression Constructs

The start codon of MYPT-75D was modified to an *NdeI* site and the complete open reading frame inserted as a *NdeI*-*NotI* fragment into pET28a for expression as NH<sub>2</sub>-terminal His<sub>6</sub>-tagged protein in *Escherichia coli* and into pUAS-HM (Parker *et al.*, 2001) for expression as His<sub>6</sub>Myc<sub>2</sub>-tagged protein in *Drosophila*. Substitution of Phe 117 to Ala in MYPT-75D<sup>F117A</sup> was by PCR-based site-directed mutagenesis.

### Phosphatase Assays

Phosphatase assays of fly extracts were as in Bennett *et al.* (2003), from three independent extracts per genotype. Recombinant His<sub>6</sub>-Sqh was purified from *E. coli* as in Skinner and Saltiel (2001) and phosphorylated with MLCK as in Ichikawa *et al.* (1996). Phosphorylated Sqh was incubated with 0.5  $\mu$ g of bacterially expressed PP1 $\beta$ 9C or PP1 $\alpha$ 87B, prepared as in Bennett *et al.* (1999). Samples were analyzed by immunoblotting using anti-Sqh antibody and antiphospho-Sqh antibody. Assays using <sup>32</sup>P-labeled Sqh and recombinant purified His<sub>6</sub>-MYPT-75D proteins were performed as Skinner and Saltiel (2001).

### Anti-phospho-Sqh Antibody

The rabbit antiphospho-Sqh antibody was raised by Moravian-Biotechnology (Brno, Czech Republic) against a phosphopeptide (KKRAQRAT[phospho-S]NVFAM) corresponding to a fragment of Sqh phosphorylated at S21.

### Immunoprecipitation from Adult *Drosophila* Extracts

Fly extracts from [*UAS-HM-MYPT-75D, Sqh-FLAG, arm-GAL4* and *UAS-HA-PP1 (PP1 $\alpha$ 87B or PP1 $\beta$ 9C)] flies, which express FLAG-tagged Sqh, Myc-tagged MYPT-75D and either HA-tagged PP1 $\alpha$ 87B or HA-tagged PP1 $\beta$ 9C, [*arm-GAL4, UAS HA-PP1 (PP1 $\alpha$ 87B or PP1 $\beta$ 9C)*] flies, which express either HA-tagged PP1 $\alpha$ 87B or HA-tagged PP1 $\beta$ 9C and [*UAS-HM-MYPT-75D* (wild-type or F117A); *arm-GAL4, UAS-HA-PP1 (PP1 $\alpha$ 87B or PP1 $\beta$ 9C)*] flies, which express either Myc-tagged MYPT-75D wild-type or F117A and either HA-tagged PP1 $\alpha$ 87B or HA-tagged PP1 $\beta$ 9C, were prepared as in Rudenko *et al.* (2003) and subjected to immunoprecipitation using anti-FLAG antibodies (M2, Sigma, St. Louis, MO), anti-DMBS antibodies (Mizuno *et al.*, 2002), or anti-Myc antibodies (A14, Santa Cruz Biotechnology, Santa Cruz, CA). After absorption on protein G bound to GammaBind Plus Sepharose (Amersham Biosciences, Amersham, United Kingdom), we analyzed immunoprecipitates and total cell extracts by immunoblotting with antibodies against FLAG, Myc and/or HA (12CA5, Roche Diagnostics, Lewes, East Sussex, United Kingdom).*

### Immunostaining

Mosaic analysis of *w flw<sup>6</sup>* clones: *w<sup>1118</sup> flw<sup>6</sup> FRT18A/FM7c* females were crossed to *w<sup>1118</sup> Ubi-GFP FRT18A*; *MKRS*, *hs-FLP86E/+* males. Progeny from this cross were allowed to develop to second and third instar larvae, heat shocked at 37.5°C for 1.5h in a water bath, and then allowed to grow up to adulthood. Dissected ovaries from 3–5-d-old *w<sup>1118</sup> flw<sup>6</sup> FRT18A/w<sup>1118</sup> Ubi-GFP FRT18A*; *MKRS*, *hs-FLP86* females were fixed for 30 min in 4% paraformaldehyde in PBS. F-actin was stained with 2.5  $\mu$ g/ml TRITC phalloidin (Sigma) in PBS, 0.3% Tween-20. Rabbit antimyosin heavy chain (Zipper) antibody, provided by Christine Field (Foe *et al.*, 2000), and antiphospho-Sqh were used at 1:600 and 1:400 in PBS, 0.3% Tween-20, respectively. Monoclonal mouse antiactin clone C4 (ICN Biomedicals, Costa Mesa, CA) was used at 1:5000. Secondary antibodies were Cy5- $\alpha$ Rb, Cy5- $\alpha$ mouse, and Cy3- $\alpha$ Rb (Jackson Labs, 1:1000). Homozygous *w<sup>1118</sup> flw<sup>6</sup>* follicle clones were visualized by the absence of Ubi-GFP.

Wing discs from *MS1096-GAL4/+; UAS-MYPT-75D (wild-type or F117A)/+* larvae and ovaries from 3–5-d-old *hs-FLP/+; UAS-MYPT-75D (wild-type or F117A)/AyGAL4*, *UAS GFP* adult flies that had been heat-shocked as second and third instar larvae, were stained with mouse monoclonal antimyc antibody (9E10, Roche) at 1:5 and antiphospho-Sqh at 1:400.

Images were collected on a Bio-Rad Radiance Plus (Richmond, CA) scanning confocal microscope and processed with Adobe Photoshop 5.0 (San Jose, CA).

## RESULTS

### Isolation of Suppressors of *flw*

To analyze the essential, nonredundant function(s) of PP1 $\beta$ 9C, we conducted an F<sub>2</sub> EMS genetic screen for dominant extragenic suppressors of *flw<sup>6</sup>*, the design of which allowed us to screen all three autosomes (~80% of the genome), but not the X chromosome. We recovered four suppressors from screening ~1000 sets of mutant autosomes. Because of the way these suppressors were isolated, they must be due to independent mutagenic events. Each of these *Su(flw)* mutations dominantly suppressed the lethality, sterility, and wing defects of *flw<sup>6</sup>*, with variable penetrance (Table 1A and Figure 1).

### Suppressors Are Not Specific for *flw<sup>6</sup>* and Do Not Increase Total PP1 Activity

*flw<sup>6</sup>* is due to a point mutation in the PP1 $\beta$  coding region (Raghavan *et al.*, 2000). Suppressors could perhaps be chaperones or binding proteins that stabilize or compensate for the changed structure of the protein. To test these possibilities we isolated a new *flw* allele, with a different molecular basis. *flw<sup>7</sup>* has a *P[lacW]* element inserted in the 5' untranslated region of PP1 $\beta$ 9C, leading to a reduced level of expression of PP1 $\beta$  (Gross, 2001). *flw<sup>7</sup>* mutant males show all the characteristic phenotypes of *flw<sup>6</sup>*, though slightly more (~2%) of the mutant males survive. The semilethality and visible phenotypes of *flw<sup>6</sup>* and *flw<sup>7</sup>* can be rescued by ectopic expression of a PP1 $\beta$ 9C cDNA (Table 1B and Figure 1). All four EMS-induced suppressors could also suppress *flw<sup>7</sup>*, indicating that they are not specifically compensating for the single amino acid change in *flw<sup>6</sup>* (Table 1). The suppressors could potentially suppress *flw<sup>6</sup>* and *flw<sup>7</sup>* through a restoration of overall phosphatase activity, for example, by increased transcription of *flw* or by some posttranscriptional mechanism. We therefore measured the total PP1 activity of select mutant combinations. None of the suppressors led to a measurable increase in PP1 activity (Figure 1I).

### PP1 $\beta$ 9C Has a Single Essential Function

Having eliminated these mechanisms for global suppression of *flw* mutants, we concluded that the suppressors are components or targets of a pathway that requires *flw*. Because single gene mutations could suppress the lethality of *flw* mutants, regulation of this pathway must be the essential, nonredundant role of *flw*. The suppressors might represent an antagonistic kinase, a substrate, or other component of

the pathway. These components might themselves be common to a small number of pathways, but still define a single nonredundant role for *flw*, e.g., a single key substrate.

### *Su(flw)* Are Loss of Function Alleles of Nonmuscle Myosin Heavy Chain and Tropomyosin 1

We mapped the four *Su(flw)* using meiotic recombination. *Su(flw)1*, 2, and 3 mapped to the tip of 2R, distal to *speck* at 2-107.0 (60B13–60F). *Su(flw)4* mapped to the third chromosome, between *curled* and *stripe* (3-55.1  $\pm$  2.2 or 86D3-4; 90D6-E2). Complementation tests revealed that *Su(flw)1*, 2, and 3 are recessive lethal alleles of a single essential gene. All three also failed to complement existing alleles of *zipper* (*zip*), which encodes nonmuscle myosin heavy chain (Young *et al.*, 1993), identifying the second chromosome *Su(flw)* as *zipper*. To test whether suppression is due to some allele-specific peculiarities, we tested a further two *zip* mutant alleles and a *zip* deficiency for their ability to suppress *flw<sup>6</sup>* and *flw<sup>7</sup>*. All three suppressed the lethality and sterility of *flw/Y* (Table 1B), indicating that suppression is not allele specific and is most likely due to a simple reduction in the amount of myosin heavy chain.

Having shown that several *zip* alleles could suppress at least two alleles of *flw*, we investigated whether *zip* mutants could suppress alleles of *PP1 $\alpha$ 87B.zip* did not suppress *PP1 $\alpha$ 87B<sup>1</sup>/PP1 $\alpha$ 87B<sup>87B $\beta$ -3</sup>*, a semilethal allelic combination, indicating that *zip* specifically suppresses PP1 $\beta$  (unpublished data). This does not preclude a role for PP1 $\alpha$ 87B in myosin regulation, but implies that this is not the only essential role of PP1 $\alpha$ 87B, consistent with the mutant phenotype of *PP1 $\alpha$ 87B* (Axton *et al.*, 1990).

Previous genetic analysis identified several *zip* interacting loci (Halsell and Kiehart, 1998), one of which, *Tropomyosin 1* (*Tm1*), maps to the same region as *Su(flw)4*. *Su(flw)4* failed to complement *Tm1<sup>02299</sup>*, identifying this suppressor as an allele of *Tm1*. *Tm1<sup>02299</sup>* suppressed both *flw<sup>6</sup>* and *flw<sup>7</sup>*, again indicating that this genetic interaction is not allele-specific (Table 1B and unpublished data). *Drosophila* has two tropomyosin genes, the other being the muscle-specific *Tm2* (Kreuz *et al.*, 1996). We therefore tested whether *Tm2<sup>18</sup>* could also suppress *flw<sup>6</sup>*, but found no such suppression (Table 1B), indicating that the essential role of PP1 $\beta$  specifically relates to regulation of nonmuscle myosin. We also tested the known upstream regulators of MRLC activity, *Rho1* and *RhoGEF2*, for interaction with *flw*. Mutations in both genes strongly suppressed *flw<sup>6</sup>* (Table 1B).

### Phosphorylation Mutants of Sqh

In view of the known role of PP1 as a MRLC phosphatase in mammals, we speculated that mutants of the phosphorylation site(s) in Sqh might interact genetically with *flw*. We obtained a set of such phosphorylation site mutants in which the critical residues Thr-20 and Ser-21 (equivalent to Thr-18 and Ser-19 in vertebrate MRLC) had been changed to Ala (*sqh<sup>A20A21</sup>*), to prevent phosphorylation, or to Glu (*sqh<sup>E20E21</sup>*), to mimic constitutive phosphorylation (Jordan and Kares, 1997; Winter *et al.*, 2001). Phosphorylation of these sites leads to myosin activation; dephosphorylation reduces myosin motor activity. These *sqh* mutant transgenes are under the control of the *sqh* promoter and are expressed at levels similar to the native protein. All these experiments were carried out in a background containing the wild-type *sqh* gene. The nonphosphorylatable *sqh<sup>A20A21</sup>* strongly suppressed both *flw<sup>6</sup>* and *flw<sup>7</sup>* mutant phenotypes (Table 1). In contrast, increasing the level of "phospho"-Sqh with the phosphorylation mimic *sqh<sup>E20E21</sup>* enhanced the weak *flw* mutant, *flw<sup>1</sup>* to lethality. By using single mutants in either

**Table 1.** Suppression of *flw*<sup>6</sup> by single-gene mutations.

A	flw <sup>6</sup> male survival [% (N)]		flw <sup>7</sup> male survival [% (N)]	
	flw <sup>6</sup> ; Su( <i>flw</i> )/+	flw <sup>6</sup> ; Bal/+	flw <sup>7</sup> ; Su( <i>flw</i> )/+	flw <sup>7</sup> ; Bal/+
<i>Su(flw)1</i>	56 (64)	0 (40)	84 (101)	0 (42)
<i>Su(flw)2</i>	91 (61)	0 (38)	83 (54)	3 (37)
<i>Su(flw)3</i>	90 (60)	0 (39)	49 (67)	6 (52)
<i>Su(flw)4</i>	65 (71)	0 (36)	67 (60)	0 (28)

B	flw <sup>6</sup> male survival [% (N)]	
	flw <sup>6</sup> ; mut/+	flw <sup>6</sup> ; Bal/+
<i>arm &gt; PP1β9C</i>	81 (107)	0 (60)
<i>zip</i> <sup>1</sup>	71 (337)	0 (167)
<i>zip</i> <sup>11X62</sup>	66 (328)	0 (216)
<i>zip</i> <sup>02957</sup>	40 (81)	0 (41)
<i>Rho1</i> <sup>E3,10</sup>	51 (262)	0 (171)
<i>RhoGEF2</i> <sup>04291</sup>	26 (113)	0 (88)
<i>Tm1</i> <sup>02299</sup>	85 (224)	1 (107)
<i>Tm2</i> <sup>18</sup>	0 (80)	4 (72)

C	flw <sup>1</sup> male survival [% (N)]		flw <sup>6</sup> male survival [% (N)]	
	flw <sup>1</sup> ; mut/+	flw <sup>1</sup> ; Bal/+	flw <sup>6</sup> ; mut/+	flw <sup>6</sup> ; Bal/+
<i>DMBS</i> <sup>E1</sup>	90 (194)	96 (139)	nd	nd
<i>Hsp70-DMBS</i> <sup>L</sup>	99 (213)	—	59 (177)	*
<i>Hsp70 &gt; MYPT-75D</i>	68 (67)	127 (59)	0 (22)	0 (25)
<i>arm &gt; MYPT-75D</i>	57 (105)	94 (101)	0 (33)	1 (68)

D	flw/Y; P[ <i>sqh</i> <sup>mut</sup> ] male survival [% (N)]				
	<i>sqh</i> <sup>A20,A21</sup>	<i>sqh</i> <sup>A21</sup>	<i>sqh</i> <sup>A20</sup>	<i>sqh</i> <sup>E21</sup>	<i>sqh</i> <sup>E20,E21</sup>
<i>flw</i> <sup>1</sup>	nd	nd	106 (185)	90* (80)	1 (96)
<i>flw</i> <sup>6</sup>	77 (274)	92 (43)	5 (112)	0 (133)	0 (63)
<i>flw</i> <sup>7</sup>	62 (52)	52 (59)	7 (65)	0 (78)	0 (56)

(A) EMS-induced suppressors efficiently suppress the lethality of both *flw*<sup>6</sup> and *flw*<sup>7</sup>. *flw*<sup>6</sup>/*FM7c* females were crossed to males heterozygous for the candidate suppressor and a balancer (*Su(flw)*/Bal); their adult progeny were scored. The percentage of expected progeny is the number of surviving male progeny divided by the number of the female progeny of the equivalent genotype × 100. N indicates total number of flies of these two classes.

(B) *flw*<sup>6</sup>/*FM7c* females were crossed to males heterozygous for the candidate suppressor and a balancer or dominant marker (mut/Bal); their adult progeny were scored. Expression of a wild type Flw/PP1β9C cDNA using the GAL4-UAS system, with the *armadillo* promoter (*arm > PP1β9C*) efficiently suppresses the lethality of *flw*<sup>6</sup>. Various *zipper* alleles with different molecular lesions also suppress, as do mutant alleles of *Rho1*, *RhoGEF2*, and *Tm1*, but not *Tm2*.

(C) *flw*<sup>1</sup>/*flw*<sup>1</sup> or *flw*<sup>6</sup>/*FM7* females were crossed to males carrying *DMBS* or *MYPT-75D* expression constructs. Overexpression of the *DMBS*<sup>L</sup> cDNA suppressed *flw*<sup>6</sup>, whereas overexpression of *MYPT-75D* did not. Overexpression of *MYPT-75D* weakly enhanced *flw*<sup>1</sup>. \* The *DMBS* constructs are viable, no balancer was required.

(D) Genetic interaction between *Sqh* phosphorylation site mutants and *flw*. *flw* mutant females were crossed to males homozygous for various point mutants affecting the phosphorylation sites of *Sqh* (Jordan and Kares, 1997; Winter *et al.*, 2001). These are autosomal insertions; all flies were wild type at the endogenous *sqh* locus. \* Though viable, most *flw*<sup>1</sup>/*Y*; P[*sqh*<sup>E21</sup>]/+ males had crumpled wings, resembling the wing phenotype of strong *flw* mutants. Alanine (A) substitutions cannot be phosphorylated and thus reduce the requirement for *flw* function while glutamic acid (E) substitutions mimic phosphorylation and so increase the requirement for *flw*. *sqh*<sup>A20,A21</sup> strongly suppresses both *flw*<sup>6</sup> and *flw*<sup>7</sup>, whereas *sqh*<sup>E20,E21</sup> is synthetic lethal with the weak, viable allele *flw*<sup>1</sup>.


nd, not done.

Thr-20 or Ser-21, we found that Ser-21 had the greater effect (Table 1). The phosphorylation state of *Sqh* is therefore closely related to the viability of *flw* mutants and hence to the essential role of PP1β.

#### Phospho-Sqh Levels Are Elevated in *flw*<sup>6</sup> Mutant Clones

To examine further the role of PP1β in actomyosin regulation, we investigated the effect of loss of PP1β9C on myosin

distribution and phosphorylation, and on actin organization. Clones of ovarian follicle cells homozygous for *flw*<sup>6</sup> were stained for actin, phosphorylated *Sqh* and myosin heavy chain (*Zip*, Figure 2). The level of phospho-*Sqh* was dramatically increased in the majority of these clones (Figure 2G), as was the level of *Zip* (Figure 2K). A nonphospho-specific anti-*Sqh* antibody showed no increase in staining in the clones (unpublished data). In most clones with elevated



**Figure 1.** Dominant suppression of *flw* by EMS-induced mutants. (A–H) Suppressors of *flw* [*Su(flw)*] can dominantly suppress *flw* wing phenotypes. (A) Wild-type (Oregon R) male. Rare *flw*<sup>6</sup>/Y and *flw*<sup>7</sup>/Y male survivors have severely crumpled wings (B and F). This is completely suppressed by expression of cDNA encoding wild-type PP1 $\beta$ 9C (e.g., *flw*<sup>7</sup>/Y; *arm-GAL4*, *UAS-PP1 $\beta$ 9C*/+, E). The wing phenotype is partially rescued by the zipper alleles *Su(flw)1* (C: *flw*<sup>6</sup>/Y; *Su(flw)1*/+, G: *flw*<sup>7</sup>/Y; *Su(flw)1*/+), *Su(flw)2* and *Su(flw)3* (unpublished data, indistinguishable from C and G) and completely rescued by the *Tm1* allele *Su(flw)4* (D: *flw*<sup>6</sup>/Y; *Su(flw)4*/+, H: *flw*<sup>7</sup>/Y; *Su(flw)4*/+). (I) Suppressor mutations do not restore PP1 activity of *flw* mutants. Extracts from wild-type (+) or *flw*<sup>6</sup> or *flw*<sup>7</sup> adult males with no suppressor or expressing a PP1 $\beta$ 9C cDNA (*arm>9C*) or heterozygous for one of the suppressor mutations were assayed for PP1 activity (plotted as the mean  $\pm$  SD; n = 3). Means that show significant difference from wild-type, as assessed by Student's *t* test at 95% confidence level, are indicated with an asterisk. Columns 1–3: Though PP1 $\beta$  represents only ~10% of the total PP1 activity, extracts from *flw* mutants have a measurable reduction in PP1 activity (see also Raghavan *et al.*, 2000). Columns 4–5: expression of a PP1 $\beta$ 9C cDNA (*arm-GAL4*, *UAS-PP1 $\beta$ 9C*) restored PP1 activity to wild-type levels (and suppressed the *flw* phenotype, see E and Table 2). Columns 6–17: flies heterozygous for any of the four EMS-induced suppressor mutations showed no increase in PP1 activity, even though these mutations suppressed the *flw* phenotype.

phospho-Sqh or Zip, the amount of filamentous actin (F-actin) was decreased, and the apical F-actin network was clearly disorganized (e.g., Figure 2B). Disruption of F-actin, visualized with TRITC-phalloidin, correlated with accumulation of cytoplasmic actin, visualized by immunofluorescence with antiactin antibody (Figure 2, A–D). Because this antibody does not appear to stain F-actin efficiently under our fixation conditions (note the absence of overlap between the actin antibody signal and the phalloidin staining in Figure 2D), we propose that there is an increase in the cytoplasmic pool of G-actin in the mutant cells. These data clearly show that the correct structure of the actin cytoskeleton, and Sqh dephosphorylation, are both dependent on PP1 $\beta$ 9C.


The phenotypes described above were not fully penetrant. On careful examination we noticed that some clones had increased levels of phospho-Sqh and myosin but normal-looking F-actin. This suggests that the F-actin disruption is a secondary consequence of increased phospho-Sqh. The increase in phospho-Sqh and Zip in these clones appeared to be concentrated toward the basal region of the cell (see Supplementary Information).

In addition to somatic clones, we analyzed germline clones mutant for *flw*<sup>6</sup>, and also generated mutant egg chambers by somatic rescue of the *flw*<sup>6</sup> phenotype with *arm-GAL4*, *UAS-PP1 $\beta$ 9C*, which expresses PP1 $\beta$ 9C in somatic cells but not in the female germline (Rorth, 1998). Like follicle cells, mutant egg chambers had elevated levels of phospho-Sqh and Zip and defects in their actin cytoskeleton organization. In particular, they had aggregates of myosin, resembling those seen in Sqh mutants (Jordan and Karess, 1997). Later, mutant egg chambers showed a clear “dumping” defect, a failure of the normally rapid transfer of the contents of the nurse cells into the oocyte at stages 10B and 11 (Figure 3, E–G). This process depends on actomyosin (Jordan and Karess, 1997; Hudson and Cooley, 2002), and so may be a consequence of the defective actin and myosin organization, but we also observed that the ring canals, which join the nurse cells to each other and to the oocyte, were defective in *flw*<sup>6</sup> mutant egg chambers. The ring canals appear normal initially, but then fail to grow properly, leading to ring canals that are much smaller than wild-type by stage 10 (Figure 3H). Small ring canals may not permit fast cytoplasmic transport from nurse cell to cytoplasm. These germline phenotypes—dumping failure, disorganized actin and myosin, and small ring canals—are all dependent on the germline genotype: they are present in mutant germline clones with wild-type follicle cells, but not in egg chambers which have wild-type germ line but predominantly mutant follicle cells.

#### MYPT-75D Is a PP1 $\beta$ -specific Binding Protein

We have shown that loss of PP1 $\beta$ 9C in clones leads to hyperphosphorylation of Sqh *in vivo*, and the lethality of strong mutants of *flw* can be suppressed by a nonphosphorylatable mutant version of Sqh. This demonstrates that *flw* regulates the phosphorylation of Sqh and that this is the essential role of PP1 $\beta$ . We also analyzed phospho-Sqh level by immunoblotting. We detected phospho-Sqh in extracts from rare hemizygous *flw*<sup>6</sup> survivors, whereas we found no detectable phospho-Sqh in extracts from wild-type flies or flies hemizygous for *flw*<sup>1</sup> (Figure 4A), presumably reflecting a low wild-type abundance relative to the sensitivity of our antibody, consistent with our immunofluorescence data. Phosphatase assays revealed that both PP1 $\beta$ 9C and PP1 $\alpha$ 87B efficiently dephosphorylate phospho-Sqh *in vitro* as immunoreactivity to our phospho-Sqh-specific antibody decreased over time on incubation with purified PP1 $\beta$  or PP1 $\alpha$  (Figure 4A). However, as purified PP1 catalytic subunits have broad substrate specificity *in vitro*, this was not surprising. The greater substrate specificity of PP1c *in vivo* is due to association of the catalytic subunit with regulatory subunits (Bollen, 2001; Cohen, 2002). Although PP1c need interact only transiently with its substrates to dephosphorylate them, it is nonetheless sometimes found in stable complexes with specific substrates, mediated by the relevant regulatory subunit.

*Drosophila* has two genes that might encode regulatory subunits capable of targeting PP1c to Sqh. These are DMBS, homologous to mammalian MYPT1/2 (Mizuno *et al.*, 2002; Tan *et al.*, 2003) and MYPT-75D, homologous to mammalian MYPT3 (Figure 5). We isolated MYPT-75D in



**Figure 2.** Loss of PP1 $\beta$  leads to hyper-phosphorylation of Sqh and disruption of the actin cytoskeleton. (A–L) Egg chambers including clones of follicle cells homozygous for *flw*<sup>6</sup> stained with TRITC-phalloidin (column 2, red in merge), and antibodies against either actin, phospho-Sqh or Zip (column 3, blue in merge). *flw*<sup>6</sup> homozygous cells are marked by absence of GFP (column 1, green in merge). (A–D) Actin organization is disrupted in cells homozygous for *flw*<sup>6</sup>. Lateral F-actin was undetectable, whereas cortical F-actin is absent or disrupted (B; also F and J). Staining with an antiactin antibody, which failed to detect filamentous actin, showed that G-actin levels are elevated in the *flw*<sup>6</sup> clone relative to adjacent normal cells (C). (E–H) Cells homozygous for *flw*<sup>6</sup> have elevated phospho-Sqh and disrupted F-actin. Phospho-Sqh in normal cells is barely detectable. Within the mutant clones, both apical and lateral F-actin is missing or disrupted (arrowhead indicates normal actin in cells adjacent to the clone). The cortical actin in the oocyte is unaffected (arrow). (I–L) Cells homozygous for *flw*<sup>6</sup> have elevated levels of Zip.

a two-hybrid screen for proteins capable of binding PP1 $\beta$ 9C (Bennett *et al.*, 1999; Bennett and Alphey, 2002). Of 36 genes identified in this screen, including homologues of known PP1 regulatory subunits such as Inhibitor-2 and NIPP1 (Bennett *et al.*, 1999; Parker *et al.*, 2002), only MYPT-75D discriminated between the PP1 isoforms. Unfortunately, sequence comparison of the different MYPT proteins has not revealed any sequences that might be responsible for the observed binding specificity of MYPT-75D. MYPT-75D contains a canonical PP1c-binding motif (R/K,<sub>x</sub>, V/I, <sub>x</sub>, F, here RHISF, residues 113–117) followed by five ankyrin repeats (residues 119–148, 151–180, 182–216, 280–310, 312–346, Figure 5) and a potential CaaX prenylation motif (CCVLM, residues 737–741). Unlike DMBS, MYPT-75D does not contain a regulatory Rho-kinase phosphorylation site.

In extracts from flies moderately overexpressing myc-MYPT-75D along with HA epitope-tagged PP1 $\beta$ 9C or PP1 $\alpha$ 87B and FLAG-tagged Sqh (using *arm-GAL4*), PP1 $\beta$ 9C coimmunoprecipitated with Sqh, but PP1 $\alpha$ 87B did not (Figure 4B), suggesting that PP1c is in a stable complex with MYPT-75D and Sqh in vivo. We further examined the PP1 binding specificities of MYPT-75D and DMBS by coimmunoprecipitation from flies. We found that DMBS bound both PP1 $\beta$ 9C and PP1 $\alpha$ 87B, whereas MYPT-75D bound only PP1 $\beta$ 9C (Figure 4C). Therefore *Drosophila* contains at least three distinct PP1-MYPT complexes: PP1 $\alpha$  + DMBS, PP1 $\beta$  + DMBS and PP1 $\beta$  + MYPT-75D. To test directly the role of the “RVXF” site in MYPT-75D for binding to PP1c, we disrupted the motif by changing the crit-

ical Phe residue to Ala. This mutant, MYPT-75D<sup>F117A</sup>, failed to bind to PP1 $\beta$ 9C (Figure 4C).


#### *flw* Interacts Differentially with Two Myosin-targeting Subunits

We examined whether DMBS or MYPT-75D interact genetically with *flw* mutants (Table 1). We found that reduction in the gene dosage of DMBS (DMBS<sup>E1/+</sup>) did not enhance *flw*<sup>1</sup>, but that overexpression of a DMBS cDNA did suppress *flw*<sup>6</sup>. Unfortunately, no mutants for MYPT-75D are available. High-level expression of the MYPT-75D cDNA (*hsp70-GAL4*, *UAS-MYPT-75D* with heat shock) is lethal to *flw*<sup>1</sup> mutants but also to wild-type (unpublished data). Moderate overexpression of a MYPT-75D cDNA (*arm-GAL4*, *UAS-MYPT-75D* or *hsp70-GAL4*, *UAS-MYPT-75D* without heat shock) did not suppress *flw*<sup>6</sup> and indeed somewhat enhanced *flw*<sup>1</sup>.

#### MYPT-75D:PP1 $\beta$ Regulates Phosphorylation of Sqh In Vitro and In Vivo

We measured the effect of MYPT-75D on PP1c activity in vitro using <sup>32</sup>P-Sqh as substrate. Recombinant MYPT-75D stimulated the Sqh phosphatase activity of PP1 $\beta$ 9C, but inhibited that of PP1 $\alpha$ 87B (Figure 4D). Disruption of the PP1c-binding motif abolished the ability of MYPT-75D to activate PP1 $\beta$ 9C, showing that binding to MYPT-75D is necessary for the stimulation of PP1 $\beta$ 9C's Sqh phosphatase activity.

We then used this nonbinding mutant to test the in vivo role of MYPT-75D-PP1 $\beta$ . Ectopic expression of wild-type



**Figure 3.** Loss of PP1 $\beta$  in egg chambers leads to abnormal ring canals and dumping defects. Cytoplasmic dumping and ring canal growth are defective in *flw*<sup>6</sup> homozygous egg chambers. Egg chambers were stained with propidium iodide to visualize DNA (A and E, red in merge) and with phalloidin to visualize F-actin (B and F, green in merge) and ring canals (D and H). Relative to wild-type (A–D) *flw*<sup>6</sup> homozygous egg chambers (E–H) have abnormal actin and nuclear structures characteristic of dumping defects. Two ring canals are shown from the same individual: (D) a normal ring canal from a stage 10 egg chamber heterozygous for *flw*<sup>6</sup> and (H) a small, abnormal ring canal from a stage 10 egg chamber homozygous for *flw*<sup>6</sup>.

MYPT-75D (MYPT-75D<sup>WT</sup>) in the wing had no phenotypic effect, but expression of MYPT-75D<sup>F117A</sup> resulted in crumpled, blistered wings (Figure 6, A and B). The wing phenotypes induced by expression of MYPT-75D<sup>F117A</sup> were suppressed by *zip*<sup>1</sup>, *Tm1*<sup>O2299</sup>, and *sqh*<sup>A20, A21</sup> and enhanced by *sqh*<sup>E20, E21</sup> (Figure 6, C and D), indicating that the effect of loss of binding of PP1 $\beta$  to MYPT-75D corresponds to changes in nonmuscle myosin activity.

When we examined levels of phospho-Sqh in wing discs from larvae of these genotypes, we saw elevated phospho-Sqh staining in cells expressing MYPT-75D<sup>F117A</sup> but not those expressing MYPT-75D<sup>WT</sup> (compare Figure 6, F and I). The myc-tagged MYPT-75D localized to the cell periphery. We also examined the effect of MYPT-75D overexpression on phospho-Sqh in follicle cell clones in the ovary. Just as we observed in wing discs, phospho-Sqh was elevated in clones expressing MYPT-75D<sup>F117A</sup> but not MYPT-75D<sup>WT</sup> (Figure 6, M and Q). Therefore, MYPT-75D-bound PP1 $\beta$  can stimulate dephosphorylation of nonmuscle MRLC both in vitro and in vivo.


## DISCUSSION

We have previously shown that PP1 $\beta$  mutants are semilethal, therefore PP1 $\beta$  is an essential gene in *Drosophila* (Raghavan *et al.*, 2000). Here we have shown that two semilethal mutant alleles of PP1 $\beta$  can be dominantly suppressed by loss-of-function extragenic mutations. The existence of single-gene extragenic suppressors indicates that PP1 $\beta$  has a single essential role, the identity of the suppressors indicates that this role is in the regulation of actin and/or myosin. Though the main defect observed in *flw* mutants is muscle detachment and degeneration, it is clear from our data that it is nonmuscle myosin, rather than muscle myosin, that is affected. Zipper and Sqh are components of nonmuscle myosin; the muscle version of Sqh, *Mlc2*, does not interact with *flw* (Raghavan *et al.*, 2000). Similarly, *Tm1*, but not the muscle-specific *Tm2*, suppresses *flw*. Disruption of nonmuscle

myosin in *flw* mutants may lead to disruption of the actin cytoskeleton and affect cell adhesion in many cell types, but seems to be most readily apparent in contractile muscle, particularly the highly specialized indirect flight muscles (Raghavan *et al.*, 2000). Though not directly involved in generation of contractile force, nonmuscle myosin seems to be necessary for the correct development of striated myofibrils (Bloor and Kiehart, 2001).

The dominant suppression of the lethality of *flw*<sup>6</sup> and *flw*<sup>7</sup> mutants by *Sqh*<sup>A20A21</sup>, coupled with the enhancement of *flw*<sup>1</sup> by *Sqh*<sup>E20E21</sup>, implies that the essential role of PP1 $\beta$  9C is related to the regulation of the phosphorylation state of Sqh. To address whether this interaction is direct or indirect we have shown that PP1 $\beta$  can directly dephosphorylate phospho-Sqh in vitro and that the two proteins coimmunoprecipitate from *Drosophila* extracts. Furthermore we have identified a new PP1 $\beta$ -specific MYPT, and shown that binding of MYPT-75D to PP1 $\beta$  stimulates dephosphorylation of nonmuscle MRLC both in vitro and in vivo. We therefore conclude that the major or only essential role of PP1 $\beta$  in *Drosophila* is to dephosphorylate Sqh and that this role is mediated, at least in part, by association with a  $\beta$ -specific MYPT protein. Although *flw*<sup>6</sup> behaves as a null allele by genetic tests (Raghavan *et al.*, 2000), we cannot rule out the possibility that it has some residual activity and that this is sufficient to perform one or more additional essential functions of PP1 $\beta$ , which for some reason require only a very low level of PP1 $\beta$  activity. PP1 $\beta$ , MRLC and MYPT proteins are highly conserved between flies and mammals, so it seems likely that dephosphorylation of MRLC is also an essential role of PP1 $\beta$  in humans.

Though PP1 $\beta$  can dephosphorylate Sqh directly and manipulating the phosphorylation state of Sqh is sufficient to suppress strong mutants of *flw*, we cannot exclude the possibility that *flw* has other substrates in the same pathway. For example, nonmuscle myosin heavy chain, which in mammals can be phosphorylated by PKC and CKII (Mu-



**Figure 4.** MYPT-75D specifically binds PP1β and stimulates its activity toward Sqh in vitro. (A) Top, levels of phosphorylated-Sqh are elevated in *flw*<sup>6</sup> mutant larvae. Equal amounts of total protein extracted from wild-type, *flw*<sup>1</sup>, and *flw*<sup>6</sup> males was subjected to immunoblotting with an antiphospho-Sqh specific antibody. For comparison, samples were run alongside unphosphorylated and phosphorylated recombinant Sqh. Phospho-Sqh was detected in *flw*<sup>6</sup> but not wild-type or *flw*<sup>1</sup> extracts. (A) Bottom, Sqh is dephosphorylated in vitro by both PP1β9C and PP1α87B. Recombinant Sqh was phosphorylated by myosin light chain kinase (MLCK) and then incubated with either PP1β9C or PP1α87B for 1, 5, or 45 min. The reaction products were separated by SDS-PAGE, blotted, and probed with either an Sqh-specific antibody (top panels) or a phospho-Sqh-specific antibody (bottom panels). Left-most panels, MLCK efficiently phosphorylated Sqh. A control reaction without (–) ATP demonstrated the specificity of the phospho-Sqh antibody for the phosphorylated form. Both PP1β9C (center panels) and PP1α87B (right panels) efficiently dephosphorylated phospho-Sqh, as determined by loss of immunoreactivity against the phospho-Sqh antibody (bottom panels) relative to reactivity against the Sqh antibody (top panels). (B) Sqh coimmunoprecipitates with PP1β9C. FLAG-tagged Sqh was immunoprecipitated from flies expressing FLAG-Sqh, HA-PP1β9C and myc-MYPT-75D. HA-PP1β9C coprecipitates with FLAG-Sqh. (C) Isoform specificity of MYPT-75D and DMBS. MYPT-75D was immunoprecipitated from flies expressing myc-tagged MYPT-75D<sup>WT</sup> or myc-tagged MYPT-75D<sup>F117A</sup> and either HA-tagged PP1β9C or HA-tagged PP1α87B. Top panel, first four lanes: PP1β9C and not PP1α87B coprecipitated with MYPT-75D<sup>WT</sup> but not MYPT-75D<sup>F117A</sup>. Middle and bottom panels, blots of total extracts showing that there were equivalent levels of MYPT-75D and HA-tagged PP1 in the various flies. The third and fourth lanes show an equivalent experiment, but precipitating DMBS with an anti-DMBS antibody, rather than MYPT-75D. Both PP1β9C and PP1α87B coprecipitate with DMBS. (D) MYPT-75D stimulates PP1β9C's Sqh-directed phosphatase activity in vitro. Wild-type and mutant MYPT-75D were preincubated for 10 min at 30°C at various concentrations with purified recombinant PP1β9C or PP1α87B, and then the reaction was started by the addition of <sup>32</sup>P-labeled Sqh. Sqh phosphatase activity without the addition of MYPT-75D was taken as 100%. PP1 activity is plotted as the mean ± SD (n = 3).

activity against the phospho-Sqh antibody (bottom panels) relative to reactivity against the Sqh antibody (top panels). (B) Sqh coimmunoprecipitates with PP1β9C. FLAG-tagged Sqh was immunoprecipitated from flies expressing FLAG-Sqh, HA-PP1β9C and myc-MYPT-75D. HA-PP1β9C coprecipitates with FLAG-Sqh. (C) Isoform specificity of MYPT-75D and DMBS. MYPT-75D was immunoprecipitated from flies expressing myc-tagged MYPT-75D<sup>WT</sup> or myc-tagged MYPT-75D<sup>F117A</sup> and either HA-tagged PP1β9C or HA-tagged PP1α87B. Top panel, first four lanes: PP1β9C and not PP1α87B coprecipitated with MYPT-75D<sup>WT</sup> but not MYPT-75D<sup>F117A</sup>. Middle and bottom panels, blots of total extracts showing that there were equivalent levels of MYPT-75D and HA-tagged PP1 in the various flies. The third and fourth lanes show an equivalent experiment, but precipitating DMBS with an anti-DMBS antibody, rather than MYPT-75D. Both PP1β9C and PP1α87B coprecipitate with DMBS. (D) MYPT-75D stimulates PP1β9C's Sqh-directed phosphatase activity in vitro. Wild-type and mutant MYPT-75D were preincubated for 10 min at 30°C at various concentrations with purified recombinant PP1β9C or PP1α87B, and then the reaction was started by the addition of <sup>32</sup>P-labeled Sqh. Sqh phosphatase activity without the addition of MYPT-75D was taken as 100%. PP1 activity is plotted as the mean ± SD (n = 3).

rakami *et al.*, 1998; Bresnick, 1999), could also be a substrate for PP1β.


What is the molecular basis of the suppression of *flw*? We believe that the key defect, both in *flw* mutants and in flies expressing MYPT-75D<sup>F117A</sup>, is the hyperphosphorylation of Sqh, particularly on Ser-21; this is directly suppressed by the nonphosphorylatable Sqh mutants. In these experiments a pool of normal Sqh remains, so we are essentially manipulating the ratio of phosphorylated and nonphosphorylated Sqh. Phosphorylation of Sqh leads to activation of the myosin motor; reduction in the amount of myosin heavy chain in *zipper*<sup>+/-</sup> presumably reduces the amount of active motor. Sqh is known to be a substrate for Rho-kinase, itself activated by a pathway that includes two more suppressors: Rho1 and RhoGEF2. Rho-kinase itself is located on the X chromosome and was therefore not accessible to our genetic screen.

*Tm1*, a strong suppressor of *flw*<sup>6</sup>, is not a member of Rho-kinase pathway but a cytoskeletal actin-binding protein (Tetzlaff *et al.*, 1996). Several functions have been ascribed to nonmuscle tropomyosin in mammals: modulation of myosin function (Strand *et al.*, 2001), actin polymerization (Wen *et*

*al.*, 2000), regulating microfilament branching (Blanchain *et al.*, 2001), and suppression of neoplastic transformation (Mahadev *et al.*, 2002). Reduction in the amount of Tm1 appears to mitigate the consequences of hyper-phosphorylated Sqh; the obvious mechanism is by reducing the binding of active myosin to actin, though Tm1 could have its effect through regulation of actin structure and polymerization.

The phenotypes we have described for *flw* somewhat resemble those of DMBS, particularly in the female germ line (Tan *et al.*, 2003) and in that they both lead to the accumulation of phospho-Sqh (Mizuno *et al.*, 2002), though DMBS mutants do not show the accumulation of myosin aggregates (Tan *et al.*, 2003). The differences in lethal phase (embryonic for DMBS, predominantly larval for *flw*) might be accounted for by maternal contribution and differences in protein stability; we were unable to investigate this further as both DMBS and *flw* are required for oogenesis. Furthermore, the *flw* suppressors *sqh*<sup>A20A21</sup>, *Rho1* and *zipper* have been shown or deduced to modify at least some of the DMBS phenotypes. This might indicate that the critical role of *flw* is mediated by DMBS. However, we have shown that DMBS is not specific for PP1β. PP1α87B is much more abundant than






**Figure 5.** MYPT-75D is a second myosin targeting subunit molecule in *Drosophila* that is most closely related to mammalian MYPT3. (A) Multiple sequence alignment of the predicted sequence of the NH<sub>2</sub>-terminal ankyrin-repeat region of MYPT proteins: hMYPT1, human MYPT1 (NP\_002471); hMYPT2, human MYPT2 (NP\_002472); hMYPT3, human MYPT3 (AAH07854); mMYPT3, mouse MYPT3 (AAG40949); dMYPT-75D, *Drosophila* MYPT-75D (AY075426); DMBS, *Drosophila* DMBS (AAF49547); cMYPT, *C. elegans* MYPT (yk603e4); cMEL-11, *C. elegans* MEL-11 (AAB47273). MYPT1/2 specific residues are in green; MYPT3 specific sequences are in yellow and common residues are in blue. The putative PP1c-binding motifs are boxed and the position of the ankyrin repeats is indicated with lines. The PP1c-binding motif in cMYPT does not conform to the consensus sequence as it has L in place of V or I. Although the first ankyrin repeat shows only weak homology to the consensus sequence, it is generally accepted to be an ankyrin repeat motif in MYPT (Skinner and Saltiel, 2001). (B) Pair-wise percentage identities between MYPT proteins over the whole length or over the NH<sub>2</sub> terminal ankyrin-repeat region. (C) Phylogenetic tree analysis of MYPT proteins (over their whole length) with *Drosophila* ankyrin (T13940) as outgroup, where branch length is proportional to sequence difference. Alignment was performed using CLUSTALW at <http://www.ebi.ac.uk/clustalw/>. The phylogenetic tree was reconstructed using the Neighbor-Joining algorithm, as implemented in the PHYLIP sequence analysis package (Phylogeny Inference Package, 3.5c Dept of Genetics, University of Washington, Seattle, WA).

PP1 $\beta$ , so *flw* mutants should have little effect on the DMBS:PP1c complex. It is possible that DMBS:PP1 $\beta$  has a unique role not shared by DMBS:PP1 $\alpha$ ; it is also possible that DMBS, which is phosphorylated by Rho-kinase, is itself directly or indirectly activated by a PP1 $\beta$ -specific phosphatase complex. However, because we have identified an additional, PP1 $\beta$ -specific MYPT, it seems much more likely that this is the key targeting subunit that mediates the essential role of PP1 $\beta$  in vivo and that the suppression of *flw* by *Rho* and *RhoGEF* is through a decrease in phosphorylation of nonmuscle MRLC by Rho-kinase.

Why do flies have two MYPTs apparently doing the same job, one PP1 $\beta$ -specific and the other not? Clearly DMBS is not completely redundant with MYPT-75D, as DMBS mutants are lethal; mutants for MYPT-75D are not available to test the converse. One possible explanation for the presence of multiple myosin targeting subunits in mammals, flies and nematodes lies at the C-termini: MYPT-75D/MYPT3 have a CaaX prenylation motif, whereas DMBS/MYPT1/2 do not.

MYPT-75D localizes to the cell periphery; this implies the existence of two different nonmuscle myosin phosphatases in different compartments of the cell: DMBS:PP1c (PP1 $\alpha$  or PP1 $\beta$ ) in the cytoplasm and MYPT-75D:PP1 $\beta$  at the plasma membrane. These myosin phosphatases have different roles and may be subject to different regulation. However, gross perturbation, such as complete removal of one complex in either DMBS or *flw* mutants, may lead to hyperphosphorylation of Sqh throughout the cell and hence to similar phenotypic consequences. Similarly, overexpression of the cytoplasmic form at a sufficiently high level may compensate for loss of the membrane-associated form: we found that overexpression of a DMBS cDNA can suppress *flw*<sup>6</sup>, indicating that greatly increased levels of DMBS:PP1 $\alpha$ 87B can partially compensate for loss of functional MYPT-75D:PP1 $\beta$ 9C complexes. A reduction in DMBS gene dose did not enhance *flw*<sup>1</sup>, indicating that DMBS is not itself the key targeting subunit for PP1 $\beta$ . Overexpression of MYPT-75D did not suppress *flw*<sup>6</sup>, presumably because MYPT-75D is not



**Figure 6.** An MYPT-75D:PP1 $\beta$ 9C regulates Sqh phosphorylation in vivo. (A–D). Effect of expression of wild-type MYPT-75D and MYPT-75D<sup>F117A</sup> in wild-type and mutant backgrounds. (A) Wings from flies ectopically expressing wild-type MYPT-75D using the wing specific driver *MS1096-GAL4* resemble wild-type. (B) Ectopic expression of MYPT-75D<sup>F117A</sup> using *MS1096-GAL4* leads to blistered and crumpled wings. The effect of MYPT-75D<sup>F117A</sup> is enhanced by *sqh*<sup>E20,E21</sup> (C) and suppressed by *sqh*<sup>A20,A21</sup> (D). (E–J) Levels of antiphospho-Sqh staining in wing imaginal discs expressing wild-type MYPT-75D or MYPT-75D<sup>F117A</sup> under the control of *MS1096-GAL4*. Two wing discs are shown, one (E–G) expressing wild-type MYPT-75D, and the other (H–J) MYPT-75D<sup>F117A</sup>, stained with antibodies against myc (column 1, red in merge) to detect ectopic myc-tagged MYPT-75D, and phospho-Sqh (column 2, blue in merge). (K–R) Levels of antiphospho-Sqh staining in clones of follicle cells expressing wild-type MYPT-75D (K–N) or MYPT-75D<sup>F117A</sup> (O–R). Egg chambers were stained with antibodies against myc (column 1, red in merge) and phospho-Sqh (column 3, blue in merge). Clones of cells expressing myc-MYPT-75D are marked by GFP (column 2, green in merge).

limiting or because increased levels of a defective MYPT-75D:PP1 $\beta$ 9C complex are not helpful. High-level overexpression of MYPT-75D was lethal to wild-type flies, and modest overexpression somewhat reduced the viability of *flw*<sup>1</sup> flies. We interpret both of these as being due to excess MYPT-75D diverting some PP1 $\beta$  from its normal role or location. *flw*<sup>1</sup> flies, in which the MYPT-75D:PP1 $\beta$ 9C myosin phosphatase is already somewhat defective, would be predicted to be more sensitive to this effect, as we observed.

In conclusion, we have shown that PP1 $\beta$  has an essential role, which is in the regulation of nonmuscle myosin, and this can be entirely explained by its role as an MRLC phosphatase. It associates with two different myosin-targeting subunits, one of which is specific for PP1 $\beta$ . These two myosin phosphatases have different roles, though sufficiently high-level expression of the putative cytoplasmic form can partially compensate for loss of the putative membrane-associated form. Loss of PP1 $\beta$ , and hence the PP1 $\beta$ -specific myosin phosphatase, leads to cytoskeletal defects and death, as does loss of the other myosin phosphatase, indicating that

each has an important, nonredundant role. All of the components of the system we have analyzed are well conserved between flies and humans, suggesting that the PP1 $\beta$ -specific myosin phosphatase may also be conserved.

#### ACKNOWLEDGMENTS

We thank Roger Karess, Yasuyoshi Nishida, Ulrich Schaefer, Myles Axton, Andrew Dingwall, and the Bloomington *Drosophila* Stock Center for flies; Roger Karess, Christine Field, and Yasuyoshi Nishida for antibodies; David Hartshorne for calmodulin and MLCK. We thank other members of the MRC *Drosophila* Cooperative Group for their help and advice, particularly to Karen Clifton, Attila Tasnadi, and Graham Knight for technical assistance. This work was supported by grants to L.A. from the Medical Research Council and BBSRC. D.B. is a Todd-Bird Research Fellow at New College, Oxford.

#### REFERENCES

Axton, J.M., Dombradi, V., Cohen, P.T., and Glover, D.M. (1990). One of the protein phosphatase 1 isoenzymes in *Drosophila* is essential for mitosis. *Cell* 63, 33–46.

- Baksa, K. *et al.* (1993). Mutations in the protein phosphatase 1 gene at 87B can differentially affect suppression of position-effect variegation and mitosis in *Drosophila melanogaster*. *Genetics* 135, 117–125.
- Bennett, D., and Alphey, L. (2002). PP1 binds dSARA to antagonise Dpp signalling. *Nat. Genet.* 31, 419–423.
- Bennett, D., Szoor, B., and Alphey, L. (1999). The chaperone-like properties of mammalian inhibitor-2 are conserved in a *Drosophila* homologue. *Biochemistry* 38, 16276–16282.
- Bennett, D., Szoor, B., Gross, S., Vereshchagina, N., and Alphey, L. (2003). Ectopic expression of inhibitors of protein phosphatase type 1 (PP1) can be used to analyze roles of PP1 in *Drosophila* development. *Genetics* 164, 235–245.
- Blanchoin, L., Pollard, T.D., and Hitchcock-DeGregori, S.E. (2001). Inhibition of the Arp2/3 complex-nucleated actin polymerisation and branch formation by tropomyosin. *Curr. Biol.* 11, 1300–1304.
- Bloor, J., and Kiehart, D. (2001). zipper nonmuscle myosin-II functions downstream of PS2 integrin in *Drosophila* myogenesis and is necessary for myofibril formation. *Dev. Biol.* 239, 215–228.
- Bollen, M. (2001). Combinatorial control of protein phosphatase-1. *Trends Biochem. Sci.* 26, 426–431.
- Bresnick, A. (1999). Molecular mechanisms of nonmuscle myosin-II regulation. *Curr. Opin. Cell Biol.* 11, 26–33.
- Cant, K., Knowles, B., Mooseker, M., and Cooley, L. (1994). *Drosophila singed*, a fascin homolog, is required for actin bundle formation during oogenesis and bristle extension. *J. Cell Biol.* 125, 369–380.
- Cohen, P. (2002). Protein phosphatase 1—targeted in many directions. *J. Cell Sci.* 115, 241–256.
- Dombrádi, V., Axton, J.M., Barker, H.M., and Cohen, P.T. (1990a). Protein phosphatase 1 activity in *Drosophila* mutants with abnormalities in mitosis and chromosome condensation. *FEBS Lett.* 275, 39–43.
- Dombrádi, V., Axton, J.M., Brewis, N.D., da Cruz e Silva, E.F., Alphey, L., and Cohen, P.T.W. (1990b). *Drosophila* contains three genes that encode distinct isoforms of protein phosphatase 1. *Eur. J. Biochem.* 194, 739–745.
- Dombrádi, V., Mann, D.J., Saunders, R.D.C., and Cohen, P.T.W. (1993). Cloning of the fourth functional gene for protein phosphatase 1 in *Drosophila melanogaster* from its chromosomal location. *Eur. J. Biochem.* 212, 177–183.
- Edwards, K., and Kiehart, D. (1996). *Drosophila* nonmuscle myosin II has multiple essential roles in imaginal disc and egg chamber morphogenesis. *Development* 122, 1499–1511.
- Foe, V.E., Field, C.M., and Odell, G.M. (2000). Microtubules and mitotic cycle phase modulate spatiotemporal distributions of F-actin and myosin II in *Drosophila* syncytial blastoderm embryos. *Development* 127, 1767–1787.
- Gross, S. (2001). Genetic and biochemical analysis of Protein Phosphatase type 1 in *Drosophila melanogaster*, DPhil, University of Oxford, Oxford.
- Halsell, S., and Kiehart, D. (1998). Second-site noncomplementation identifies genomic regions required for *Drosophila* nonmuscle myosin function during morphogenesis. *Genetics* 148, 1845–1863.
- Hartshorne, D. (1998). Myosin phosphatase: subunits and interactions. *Acta Physiol. Scand.* 164, 483–493.
- Holst, J., Sim, A., and Ludowyke, R. (2002). Protein phosphatases 1 and 2A transiently associate with myosin during the peak rate of secretion from mast cells. *Mol. Biol. Cell* 13, 1083–1098.
- Hudson, A., and Cooley, L. (2002). Understanding the function of actin-binding proteins through genetic analysis of *Drosophila* oogenesis. *Annu. Rev. Genet.* 36, 455–488.
- Ichikawa, K., Hirano, K., Ito, M., Tanaka, J., Nakano, T., and Hartshorne, D.J. (1996). Interactions and properties of smooth muscle myosin phosphatase. *Biochemistry* 35, 6313–6320.
- Jordan, P., and Kares, R. (1997). Myosin light chain-activating phosphorylation sites are required for oogenesis in *Drosophila*. *J. Cell Biol.* 139, 1805–1819.
- Kaibuchi, K., Kuroda, S., and Amano, M. (1999). Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. *Annu. Rev. Biochem.* 68, 459–486.
- Kares, R.E., Chang, X.J., Edwards, K.A., Kulkarni, S.J., Aguilera, I., and Kiehart, D.P. (1991). The regulatory light chain of nonmuscle myosin is encoded by spaghetti-squash, a gene required for cytokinesis in *Drosophila*. *Cell* 65, 1177–1189.
- Kiss, E., Muranyi, A., Csontos, C., Gergely, P., Ito, M., Hartshorne, D., and Erdodi, F. (2002). Integrin-linked kinase phosphorylates the myosin phosphatase target subunit at the inhibitory site in platelet cytoskeleton. *Biochem. J.* 365, 79–87.
- Kreuz, A.J., Simcox, A., and Maughan, D. (1996). Alterations in flight muscle ultrastructure and function in *Drosophila* tropomyosin mutants. *J. Cell Biol.* 135, 673–687.
- MacDonald, J., Borman, M., Muranyi, A., Somlyo, A., Hartshorne, D., and Haystead, T. (2001). Identification of the endogenous smooth muscle myosin phosphatase-associated kinase. *Proc. Natl. Acad. Sci. USA* 98.
- Mahadev, K., Raval, G., Shantaram, B., Willingham, M.C., Lange, E.M., Vonderhaar, B., Salomon, D., and Prasad, G.L. (2002). Suppression of the transformed phenotype of breast cancer by Tropomyosin-1. *Exp. Cell Res.* 279, 40–51.
- Matsumura, F., Totsukawa, G., Yamakita, Y., and Yamashiro, S. (2001). Role of myosin light chain phosphorylation in the regulation of cytokinesis. *Cell Struct. Funct.* 26, 639–644.
- Mizuno, T., Tsutsui, K., and Nishida, Y. (2002). *Drosophila* myosin phosphatase and its role in dorsal closure. *Development* 129, 1215–1223.
- Murakami, N., Chauhan, V.P.S., and Elzinga, M. (1998). Two nonmuscle isoforms expressed in rabbit brains: filament forming properties, the effects of phosphorylation by protein kinase C and casein kinase II, and location of the phosphorylation sites. *Biochemistry* 37, 1989–2003.
- Parker, L., Gross, S., and Alphey, L. (2001). Vectors for the expression of tagged proteins in *Drosophila*. *BioTechniques* 31, 1280–1286.
- Parker, L., Gross, S., Beullens, M., Bollen, M., Bennett, D., and Alphey, L. (2002). Functional interaction between NIPP1 and PP1 in *Drosophila*: consequences of over-expression of NIPP1 in flies and suppression by co-expression of PP1. *Biochem. J.* 368, 789–797.
- Raghavan, S. *et al.* (2000). Protein phosphatase 1beta is required for the maintenance of muscle attachments. *Curr. Biol.* 10, 269–272.
- Rorth, P. (1998). Gal4 in the *Drosophila* female germline. *Mech. Dev.* 78, 113–118.
- Rudenko, A., Bennett, D., and Alphey, L. (2003). Trithorax interacts with type 1 serine/threonine protein phosphatase *Drosophila*. *EMBO Rep.* 4, 59–63.
- Sellers, J. (2000). Myosins: a diverse superfamily. *Biochim. Biophys. Acta* 1496, 3–22.
- Skinner, J., and Saltiel, A. (2001). Cloning and identification of MYPT 3, a prenylatable myosin targeting subunit of protein phosphatase 1. *Biochem. J.* 356, 257–267.
- Somlyo, A., and Somlyo, A. (2000). Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. *J. Physiol.* 522, 177–185.
- Strand, J., Nili, M., Homsher, E., and Tobacman, L.S. (2001). Modulation of myosin function by isoform-specific properties of *Saccharomyces cerevisiae* and muscle tropomyosin. *J. Biol. Chem.* 276, 34832–34839.
- Tan, C., Stronach, B., and Perrimon, N. (2003). Roles of myosin phosphatase during *Drosophila* development. *Development* 130, 671–681.
- Tetzlaff, M.T., Jackle, H., and Pankratz, M.J. (1996). Lack of *Drosophila* cytoskeletal tropomyosin affects head morphogenesis and the accumulation of oscar mRNA required for germ cell formation. *EMBO J.* 15, 1247–1254.
- Varmuza, S., Jurisicova, A., Okano, K., Hudson, J., Boekelheide, K., and Shipp, E.B. (1999). Spermiogenesis is impaired in mice bearing a targeted mutation in the protein phosphatase 1c $\gamma$  gene. *Dev. Biol.* 205, 98–110.
- Wen, K.K., Kuang, B., and Rubenstein, P.A. (2000). Tropomyosin-dependent filament formation by a polymerisation-defective mutant yeast actin (V266G, L267G). *J. Biol. Chem.* 275, 40594–40600.
- Winter, C., Wang, B., Ballew, A., Royou, A., Kares, R., Axelrod, J., and Luo, L. (2001). *Drosophila* Rho-associated kinase (Drok) links Frizzled-mediated planar cell polarity signaling to the actin cytoskeleton. *Cell* 105, 81–91.
- Young, P., Richman, A., Ketchum, A., and Kiehart, D. (1993). Morphogenesis in *Drosophila* requires nonmuscle myosin heavy chain function. *Genes Dev.* 7, 29–41.